COLLAGEN STOCK ADVANCES 17% TO 19-3/4 IN AUGUST AS FIRM PREDICTS 1997 IMPROVEMENT FROM AESTHETIC TECHNOLOGIES BUSINESS; O-T-C INDEX RECOUPS 4.4%
This article was originally published in The Gray Sheet
Executive Summary
Collagen's ability to weather lower Contigen incontinence implant sales in fiscal 1996, combined with the firm's predicted improvement in operating income in 1997, apparently helped inspire investor confidence in the stock. The issue reversed a two month slide and advanced 2-7/8 points, or 17%, to 19-3/4 in August, regaining some ground it relinquished in June and July, when it lost more than 20% of its value.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.